The Active Care Group (ACG) and Montreux Capital Management (UK) (MCM UK) have both been shortlisted in categories at this year’s LaingBuisson awards.

The LaingBuisson awards, now in their 15th year, celebrate the achievements of companies across various sectors within the UK healthcare industry.

ACG have been shortlisted for the Specialist Care award and the Christchurch Group, part of the ACG portfolio, have been recognised for the Rehabilitation award. MCM UK have been nominated for the Investor Award which recognises successful investment strategies and high returns.

Oliver Harris, MCM UK CEO, said: “It’s an honour to be recognised with the Active Care Group for our collective achievements in what was a challenging year due to the COVID-19 pandemic. The professionalism and high-quality services levels we have maintained throughout the years served us well during this period. Best of luck to both the Active Care Group and Christchurch Group.”

The awards will take place on Thursday 19th November 2020 at the Park Plaza Westminster Bridge, London.

Full list of finalists are available here on the LaingBuisson website.

Find Us

Thameside House
Hurst Road
East Molesey
KT8 9AY

T: + 44 (0) 1932 860 140
E: info@montreuxcm.com

Information on this webpage relates to and is provided by Montreux Capital Management

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Montreux Capital Management do not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.

ACCEPT